Profile data is unavailable for this security.
About the company
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
- Revenue in USD (TTM)0.00
- Net income in USD-444.28m
- Incorporated2000
- Employees376.00
- LocationMadrigal Pharmaceuticals Inc200 Barr Harbor Dr Ste 400WEST CONSHOHOCKEN 19428-2978United StatesUSA
- Phone+1 (404) 380-9263
- Fax+1 (302) 655-5049
- Websitehttps://www.madrigalpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alkermes Plc | 1.73bn | 599.95m | 4.16bn | 2.10k | 7.03 | 3.32 | 6.27 | 2.41 | 3.50 | 2.53 | 10.05 | 7.42 | 0.8532 | 1.32 | 5.81 | 821,991.40 | 29.65 | 1.34 | 38.77 | 1.74 | 85.31 | 83.32 | 34.76 | 2.12 | 2.77 | -- | 0.1878 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
Immunitybio Inc | 302.00k | -600.96m | 4.24bn | 628.00 | -- | -- | -- | 14,037.46 | -1.05 | -1.05 | 0.0005 | -1.02 | 0.0008 | -- | 0.1677 | 480.89 | -161.65 | -112.76 | -946.50 | -316.07 | -- | -- | -199,138.70 | -37,700.74 | -- | -1.92 | 5.32 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
Crinetics Pharmaceuticals Inc | 1.97m | -235.46m | 4.25bn | 290.00 | -- | 4.83 | -- | 2,151.26 | -3.77 | -3.77 | 0.0315 | 11.14 | 0.0031 | -- | 0.3653 | 6,806.90 | -35.57 | -42.53 | -37.86 | -45.36 | -- | -- | -11,641.13 | -5,446.39 | -- | -- | 0.00 | -- | -15.28 | 10.57 | -30.88 | -- | 34.65 | -- |
Immunovant Inc | 0.00 | -259.34m | 4.38bn | 207.00 | -- | 7.07 | -- | -- | -1.89 | -1.89 | 0.00 | 4.24 | 0.00 | -- | -- | 0.00 | -48.37 | -- | -52.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -22.93 | -- | -- | -- |
Nuvalent Inc | 0.00 | -145.51m | 5.20bn | 106.00 | -- | 7.69 | -- | -- | -2.41 | -2.41 | 0.00 | 10.47 | 0.00 | -- | -- | 0.00 | -24.88 | -- | -26.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.20 | -- | -- | -- |
Viking Therapeutics Inc | 0.00 | -93.72m | 5.50bn | 28.00 | -- | 5.88 | -- | -- | -0.9305 | -0.9305 | 0.00 | 8.47 | 0.00 | -- | -- | 0.00 | -16.76 | -21.91 | -17.52 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
Madrigal Pharmaceuticals Inc | 0.00 | -444.28m | 5.74bn | 376.00 | -- | 6.55 | -- | -- | -23.08 | -23.08 | 0.00 | 41.13 | 0.00 | -- | -- | 0.00 | -62.81 | -62.09 | -73.92 | -74.81 | -- | -- | -- | -- | 9.39 | -- | 0.1201 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
Krystal Biotech Inc | 95.95m | 57.16m | 5.92bn | 229.00 | 110.15 | 7.40 | 93.34 | 61.70 | 1.88 | 1.88 | 3.38 | 28.02 | 0.1385 | -- | -- | 418,991.30 | 8.25 | -11.50 | 8.78 | -12.01 | 94.25 | -- | 59.57 | -492.85 | 12.42 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
Summit Therapeutics Inc | 0.00 | -116.03m | 6.54bn | 105.00 | -- | 147.83 | -- | -- | -0.1657 | -0.1657 | 0.00 | 0.063 | 0.00 | -- | -- | 0.00 | -53.76 | -77.32 | -59.38 | -86.35 | -- | -- | -- | -20,989.46 | -- | -118.81 | 0.6934 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
Exelixis Inc | 1.85bn | 205.05m | 6.56bn | 1.31k | 34.81 | 3.12 | 28.47 | 3.55 | 0.6466 | 0.6466 | 5.84 | 7.21 | 0.621 | 3.12 | 7.78 | 1,409,653.00 | 6.90 | 8.86 | 7.82 | 9.91 | 95.70 | 96.30 | 11.10 | 15.43 | 3.41 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
Tempus AI Inc | 562.02m | -293.25m | 6.57bn | -- | -- | -- | -- | 11.69 | -1.78 | -1.78 | 3.41 | -2.06 | -- | -- | -- | -- | -- | -- | -- | -- | 54.25 | -- | -39.94 | -- | 1.13 | -16.02 | 4.19 | -- | 65.85 | -- | 20.35 | -- | -- | -- |
Cytokinetics, Inc. | 3.75m | -530.60m | 6.59bn | 423.00 | -- | -- | -- | 1,756.50 | -5.40 | -5.40 | 0.0382 | -3.78 | 0.0044 | -- | 4.08 | 8,869.98 | -62.50 | -43.14 | -69.19 | -47.22 | -- | -- | -14,141.74 | -540.47 | -- | -15.26 | 2.78 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
Halozyme Therapeutics, Inc. | 862.99m | 318.80m | 6.97bn | 373.00 | 22.65 | 39.16 | 17.38 | 8.07 | 2.42 | 2.42 | 6.54 | 1.40 | 0.4874 | 1.34 | 4.42 | 2,313,644.00 | 18.01 | 18.22 | 19.22 | 21.97 | 78.50 | 79.05 | 36.94 | 39.36 | 5.36 | 966.62 | 0.8941 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
Ionis Pharmaceuticals Inc | 776.62m | -384.77m | 7.00bn | 927.00 | -- | 23.59 | -- | 9.01 | -2.67 | -2.67 | 5.40 | 2.03 | 0.275 | 0.379 | 81.52 | 837,777.80 | -13.62 | -6.30 | -15.20 | -7.44 | 98.72 | 98.75 | -49.54 | -21.23 | 7.28 | -- | 0.8114 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
Blueprint Medicines Corp | 282.21m | -288.29m | 7.16bn | 645.00 | -- | 23.04 | -- | 25.37 | -4.82 | -4.82 | 4.59 | 4.96 | 0.2499 | 0.3531 | 6.18 | 430,853.40 | -25.53 | -29.92 | -30.68 | -34.06 | 96.97 | -- | -102.15 | -116.65 | 3.61 | -23.37 | 0.4352 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
Data as of Jul 22 2024. Currency figures normalised to Madrigal Pharmaceuticals Inc's reporting currency: US Dollar USD
63.07%Per cent of shares held by top holders
Holder | Shares | % Held |
---|---|---|
Janus Henderson Investors US LLCas of 31 Mar 2024 | 2.58m | 12.11% |
Baker Bros. Advisors LPas of 25 Jun 2024 | 1.98m | 9.30% |
Avoro Capital Advisor LLCas of 31 Mar 2024 | 1.94m | 9.12% |
Paulson & Co., Inc.as of 31 Mar 2024 | 1.78m | 8.33% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.63m | 7.64% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.08m | 5.08% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 788.19k | 3.70% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 624.94k | 2.93% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 605.52k | 2.84% |
Perceptive Advisors LLCas of 31 Mar 2024 | 429.95k | 2.02% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.